Carlo Rizzuto
InvestorManaging Director at Versant Ventures
New York, New York
Writes $100K – $5M checks · typically $1.5M
About
Carlo Rizzuto, a PhD virologist-turned-VC who pioneered and championed epitranscriptomics and backed Gotham Therapeutics early, is a hands-on builder who often serves as acting CEO/CBO to create first-wave biology companies.
Invests in
BiotechHealthtechMedical Devices
Experience
- Versant VenturesManaging Directorcurrent2022 — presentNew York, New York, United States
- Versant VenturesPartner2012 — 2022New York City Metropolitan Area
- Highline TherapeuticsCEO2015 — 2022New York City Metropolitan Area
- NovartisGlobal Program Team Director2010 — 2012
- Novartis International AGAssistant to the CEO2010
- NovartisAssistant to CEO - Pharmaceuticals2009 — 2010
- McKinsey & CompanyAssociate Principal2002 — 2008
- engeneOSBusiness Development Manager2000 — 2002
Education
- Harvard UniversityPhD, Virology1993 — 1999
- University of VirginiaBA, Biology1988 — 1992
- Miller Place High School
Skills & more
+6 more
Molecular BiologyVenture CapitalDrug DevelopmentBusiness DevelopmentCross-functional Team LeadershipLife SciencesFrom Carlo's professional profile.
Same school
Also attended Harvard University1,171
+ 1,165 more
Also attended University of Virginia316
+ 310 more
Shared employers
Also worked at Versant Ventures29
+ 23 more
Also worked at Novartis105
+ 99 more
Also worked at McKinsey & Company1,127
+ 1,121 more
Deals · 8
Nexo Therapeutics, Inc.Board seat
via Versant Ventures · filed Mar 2026 · $60M raise
Pep2Tango TherapeuticsBoard seat
via Versant Ventures · filed Nov 2024 · $16.7M raise
Jnana Therapeutics Inc.Board seat
via Versant Ventures · filed Jan 2024 · $107M raise
858 Therapeutics, Inc.Board seat
via Versant Ventures · filed May 2021 · $40M raise
Graphite Bio, Inc.Board seat
via Versant Ventures · filed Mar 2021 · $150.7M raise
Century Therapeutics, Inc.Board seat
via Versant Ventures · filed Mar 2021 · $160M raise
Pandion Therapeutics HoldcoBoard seat
via Versant Ventures · filed Apr 2020 · $80M raise
Pandion TherapeuticsBoard seat
via Versant Ventures · filed Jan 2018 · $57.6M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Versant Ventures
Network7
Investors connected to Carlo in public investor directories — a warm-intro map.






















.jpg)







